These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 26863535)

  • 1. Simvastatin Sodium Salt and Fluvastatin Interact with Human Gap Junction Gamma-3 Protein.
    Marsh A; Casey-Green K; Probert F; Withall D; Mitchell DA; Dilly SJ; James S; Dimitri W; Ladwa SR; Taylor PC; Singer DR
    PLoS One; 2016; 11(2):e0148266. PubMed ID: 26863535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.
    Neuvonen PJ; Backman JT; Niemi M
    Clin Pharmacokinet; 2008; 47(7):463-74. PubMed ID: 18563955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of cytochrome P450 expression by inhibitors of hydroxymethylglutaryl-coenzyme A reductase in primary cultured rat hepatocytes and in rat liver.
    Kocarek TA; Reddy AB
    Drug Metab Dispos; 1996 Nov; 24(11):1197-204. PubMed ID: 8937853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of connexin expression after balloon injury: possible mechanisms for antiproliferative effect of statins.
    Wang L; Chen J; Sun Y; Zhang F; Zhu J; Hu S; Wang DH
    Am J Hypertens; 2005 Sep; 18(9 Pt 1):1146-53. PubMed ID: 16245407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interaction of different statins with model membranes by NMR data.
    Galiullina LF; Aganova OV; Latfullin IA; Musabirova GS; Aganov AV; Klochkov VV
    Biochim Biophys Acta Biomembr; 2017 Mar; 1859(3):295-300. PubMed ID: 27989745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors.
    Garnett WR
    Am J Health Syst Pharm; 1995 Aug; 52(15):1639-45. PubMed ID: 7583826
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical pharmacokinetics of fluvastatin.
    Scripture CD; Pieper JA
    Clin Pharmacokinet; 2001; 40(4):263-81. PubMed ID: 11368292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing the Interactions of Statins with Human Adenylate Kinase Isoenzyme 1: Fluorescence and Enzyme Kinetic Studies.
    Wujak M; Kozakiewicz A; Ciarkowska A; Loch JI; Barwiolek M; Sokolowska Z; Budny M; Wojtczak A
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus.
    Appel S; Rüfenacht T; Kalafsky G; Tetzloff W; Kallay Z; Hitzenberger G; Kutz K
    Am J Cardiol; 1995 Jul; 76(2):29A-32A. PubMed ID: 7604792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simvastatin compared to fluvastatin in the reduction of serum lipids and apolipoproteins in patients with ischaemic heart disease and moderate hypercholesterolaemia.
    Sigurdsson G; Haraldsdottir SO; Melberg TH; Tikkanen MJ; Miettinen TE; Kristianson KJ
    Acta Cardiol; 1998; 53(1):7-14. PubMed ID: 9638964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatal rhabdomyolysis in a patient with liver cirrhosis after switching from simvastatin to fluvastatin.
    Baek SD; Jang SJ; Park SE; Ok TJ; Leem J; Lee HS; Park SJ; Kim TH
    J Korean Med Sci; 2011 Dec; 26(12):1634-7. PubMed ID: 22148003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of interactions of simvastatin, pravastatin, fluvastatin, and pitavastatin with bovine serum albumin: multiple spectroscopic and molecular docking.
    Shi JH; Wang Q; Pan DQ; Liu TT; Jiang M
    J Biomol Struct Dyn; 2017 May; 35(7):1529-1546. PubMed ID: 27484332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An in vitro study of the hydroxyl radical scavenging property of fluvastatin, and HMG-CoA reductase inhibitor.
    Suzumura K; Yasuhara M; Tanaka K; Odawara A; Narita H; Suzuki T
    Chem Pharm Bull (Tokyo); 1999 Jul; 47(7):1010-2. PubMed ID: 10434403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluvastatin and fluvastatin extended release: a clinical and safety profile.
    Asberg A; Holdaas H
    Expert Rev Cardiovasc Ther; 2004 Sep; 2(5):641-52. PubMed ID: 15350166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging issues of connexin channels: biophysics fills the gap.
    Harris AL
    Q Rev Biophys; 2001 Aug; 34(3):325-472. PubMed ID: 11838236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statin induced myotoxicity: the lactone forms are more potent than the acid forms in human skeletal muscle cells in vitro.
    Skottheim IB; Gedde-Dahl A; Hejazifar S; Hoel K; Asberg A
    Eur J Pharm Sci; 2008 Apr; 33(4-5):317-25. PubMed ID: 18294823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical implications of the biopharmaceutical properties of fluvastatin.
    Deslypere JP
    Am J Cardiol; 1994 May; 73(14):12D-17D. PubMed ID: 8198018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HMG-CoA reductase inhibitors reduce interleukin-6 synthesis in human vascular smooth muscle cells.
    Ito T; Ikeda U; Shimpo M; Ohki R; Takahashi M; Yamamoto K; Shimada K
    Cardiovasc Drugs Ther; 2002 Mar; 16(2):121-6. PubMed ID: 12090904
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HMG-CoA reductase inhibitors prevent migration of human coronary smooth muscle cells through suppression of increase in oxidative stress.
    Yasunari K; Maeda K; Minami M; Yoshikawa J
    Arterioscler Thromb Vasc Biol; 2001 Jun; 21(6):937-42. PubMed ID: 11397700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.